(Bloomberg) — Johnson & Johnson started a trial of its experimental Ebola vaccine in the U.K. and said it will produce 2 million courses of the shot this year.

The first volunteers in Oxford have received an initial dose, and the trial aims to recruit 72 people by the end of January, the New Brunswick, New Jersey-based company said in a statement today. Other tests are planned for the U.S., Kenya, Uganda and Tanzania. J&J has produced more than 400,000 courses of vaccine for use in large-scale trials by April, and could produce as many as 5 million courses over 12 to 18 months.

Want to continue reading?
Become a Free
PropertyCasualty360 Digital Reader.


  • All PropertyCasualty360.com news coverage, best practices, and in-depth analysis.
  • Educational webcasts, resources from industry leaders, and informative newsletters.
  • Other award-winning websites including BenefitsPRO.com and ThinkAdvisor.com.

Already have an account?

Dig Deeper



Join PropertyCasualty360

Don’t miss crucial news and insights you need to make informed decisions for your P&C insurance business. Join PropertyCasualty360.com now!

  • Unlimited access to PropertyCasualty360.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including BenefitsPRO.com, ThinkAdvisor.com and Law.com
  • Exclusive discounts on PropertyCasualty360, National Underwriter, Claims and ALM events

Already have an account? Sign In Now
Join PropertyCasualty360

Copyright © 2023 ALM Global, LLC. All Rights Reserved.